Leerink Partnrs Comments on HCA Healthcare FY2027 Earnings

HCA Healthcare, Inc. (NYSE:HCA) – Research analysts at Leerink Partnrs boosted their FY2027 earnings per share estimates for HCA Healthcare in a report issued on Monday, January 27th. Leerink Partnrs analyst W. Mayo now anticipates that the company will post earnings per share of $32.55 for the year, up from their prior estimate of $30.68. The consensus estimate for HCA Healthcare’s current full-year earnings is $21.75 per share.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter in the previous year, the firm earned $5.90 earnings per share.

HCA has been the subject of a number of other reports. Truist Financial dropped their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Wells Fargo & Company downgraded shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $400.00 to $320.00 in a research report on Monday, November 25th. Bank of America reduced their price objective on shares of HCA Healthcare from $380.00 to $370.00 and set a “buy” rating on the stock in a research note on Monday. TD Cowen cut their price target on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Finally, KeyCorp dropped their price objective on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $382.19.

HCA Healthcare Stock Down 0.3 %

NYSE HCA opened at $327.80 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare has a 1-year low of $289.98 and a 1-year high of $417.14. The company has a 50 day moving average of $313.28 and a 200-day moving average of $353.27. The company has a market cap of $83.03 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 1.09 and a beta of 1.64.

HCA Healthcare Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be given a dividend of $0.72 per share. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, March 17th. HCA Healthcare’s payout ratio is 11.85%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On HCA Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of HCA. Terra Nova Asset Management LLC raised its position in HCA Healthcare by 0.3% in the third quarter. Terra Nova Asset Management LLC now owns 8,112 shares of the company’s stock worth $3,297,000 after acquiring an additional 26 shares during the period. Massmutual Trust Co. FSB ADV grew its stake in HCA Healthcare by 7.4% during the third quarter. Massmutual Trust Co. FSB ADV now owns 421 shares of the company’s stock valued at $171,000 after acquiring an additional 29 shares in the last quarter. Waldron Private Wealth LLC grew its stake in HCA Healthcare by 1.8% during the third quarter. Waldron Private Wealth LLC now owns 1,681 shares of the company’s stock valued at $683,000 after acquiring an additional 29 shares in the last quarter. Brookstone Capital Management lifted its position in HCA Healthcare by 0.7% during the third quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock valued at $1,652,000 after purchasing an additional 30 shares during the last quarter. Finally, UMB Bank n.a. lifted its position in HCA Healthcare by 2.4% during the third quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock valued at $529,000 after purchasing an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.